Apatinib is also an anti-angiogenesis molecular targeted drug, which by highly specific inhibition of the activity of the VEGFR-2 tyrosine kinase pathway, while blocking the signal transduction pathway after VEGF and its receptor are combined, it has been used for second-line treatment of gastric cancer [55]. The gene discussed is KDR; the disease is gastric cancer.